Theorem Clinical Research

Drug Sponsors

Sysmex acquires Inostics

Wednesday, September 25, 2013 12:29 PM

Privately-held biotech company Indivumed, based in Hamburg, Germany, has announced that Inostics and its Baltimore-based subsidiary have been sold to Sysmex, a developer and manufacturer of instruments, reagents and software needed for in-vitro diagnostics, headquartered in Japan.

More... »

PRA, RPS merger completed

Wednesday, September 25, 2013 12:23 PM

CRO PRA International has completed its merger with ReSearch Pharmaceutical Services (RPS) and the closing of the acquisition by Kohlberg Kravis Roberts.  

More... »

GSK inks agreement with BARDA to supply anthrax treatment

Friday, September 20, 2013 11:32 AM

GlaxoSmithKline has signed a new four-year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), for the provision of its inhalation anthrax treatment, raxibacumab. The U.S. government is purchasing the medicine as a counter measure against a potential bioterrorist attack.

More... »

Medtronic opens Ireland Innovation Center

Wednesday, September 18, 2013 12:44 PM

Medtronic, a Minneaplis, Minn.-based medical technology provider, has opened a new Customer Innovation Center (CIC) in Galway, Ireland, providing state-of-the-art facilities for physicians and Medtronic engineers to develop new therapies that will improve clinical outcomes, provide economic value and increase access to quality healthcare for patients around the world.

More... »

Boston Scientific opens China Innovation Center

Wednesday, September 18, 2013 11:25 AM

Boston Scientific, a global medical technology company, has opened the China branch of the Boston Scientific Institute for Advancing Science (IAS) as well as its new Innovation Center. Boston Scientific expects to foster local talent while sustainably developing innovative technologies uniquely suited to the China market.

More... »

Cardiome, Tzamal Medical form commercialization agreement

Wednesday, September 18, 2013 10:57 AM

Cardiome Development, a subsidiary of Cardiome Pharma, and Tzamal Medical Group are collaborating to sell and distribute Brinavess (vernakalant intravenous) exclusively in Israel. Tzamal Medical, a private group of companies providing medical devices and equipment for the healthcare industry, has agreed to specific annual commercial goals for Brinavess, which was approved in Europe for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Financial details of the agreement have not been disclosed.

More... »

Chiesi to acquire 100% of Cornerstone Therapeutics

Wednesday, September 18, 2013 09:04 AM

European pharma company Chiesi Farmaceutici will acquire 100% of Cornerstone Therapeutics, a North Carolina-based specialty pharmaceutical company commercializing products for the U.S. hospital and adjacent specialty markets.

More... »

Celtaxsys restructures, enhances operational focus

Monday, September 16, 2013 08:43 AM

Celtaxsys, an Atlanta-based pharmaceutical discovery and development company, has restructured its management and operations to focus on development of its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis.

More... »

Recordati acquires Laboratorios Casen Fleet

Wednesday, September 11, 2013 01:40 PM

Recordati, an international pharmaceutical group, has acquired Laboratorios Casen Fleet, a Spanish pharmaceutical company headquartered in Madrid with production facilities in Zaragoza. The transaction is valued at $123.3 million and will be funded from existing liquidity.

More... »

Sorrento Therapeutics completes IgDraSol merger

Wednesday, September 11, 2013 01:31 PM

Sorrento Therapeutics has completed its merger with Igdrasol, a privately-held company focused on the development of cancer therapeutics. Igdrasol shareholders will receive the equivalent of 3,047,968 million shares of Sorrento's common stock. Reflecting Sorrento's recent reverse stock split, and based on the closing share price on Sept. 6, 2013, the transaction is valued at $28.2 million.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs